- FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 1mo ago↗ source
- At BIO, tension over China biotech deal regulation looms<figure><div><img src="https://imgproxy.divecdn.com/QMMgdLWmV9_RV75ozi_JOVMqLcnMq3yXkrVCs0nJ7_U/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTgyOTQ2OTI4LmpwZ…BioPharma Dive · 1mo ago↗ source
- Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda<p>Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillio…